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Ataxia-telangiectasiaAtaxia-telangiectasia (AT) is an autosomal recessive genetic disease characterized by immunological
deﬁciencies, neurological degeneration, developmental abnormalities and an increased risk of cancer.
Ataxia-telangiectasia group D (ATDC) was initially described as a gene related to AT. Ataxia-telangiectasia
group D, also known as TRIM29, is structurally a member of the tripartite motif (TRIM) family of proteins,
some of which have been reported to be highly expressed in some human carcinomas, but the involvement of
TRIM29 in carcinogenesis has not been fully elucidated. In this study, we found by using yeast two-hybrid
screening that TRIM29 binds to Tip60, which has been reported as a cellular acetyltransferase protein.
Overexpression of TRIM29 promoted degradation and changed localization of Tip60 and reduced acetylation
of p53 at lysine 120 by Tip60, resulting in enhancement of cell growth and transforming activity. In addition,
we found that TRIM29 suppresses apoptosis induced by UV irradiation in HCT116 cell lines. These ﬁndings
suggest that TRIM29 functions as an oncogene that promotes tumor growth.mistry, Hokkaido University
ro, Hokkaido 060-8638, Japan.
yama).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Ataxia-telangiectasia (AT) group D (ATDC) has been reported as one
of the suppressive genes responsible for the genetic disorder ataxia-
telangiectasia (AT) [1]. AT is a human autosomal recessive genetic
disease characterized by immunological deﬁciencies, neurological
degeneration, developmental abnormalities and an increased risk of
cancer. Cells isolated fromAT patients showhypersensitivity to ionizing
radiation, radio-resistant DNA synthesis, elevated recombination, cell
cycle abnormalities and aberrant cytoskeletal organization [2].
The ATDC gene is located at chromosome 11q23 and encodes a 588
amino acid protein. ATDC protein has been reported to be amember of
the tripartite motif (TRIM) protein family with multiple zinc-ﬁnger
motifs and an adjacent leucine-zipper motif that may allow ATDC to
form homo- or heterodimers [1]. Therefore, ATDC is also known as
TRIM29. TRIM proteins have a series of conserved domains, which
include a RING, a B box type 1 (B1) and B box type 2 (B2), and a coiled-
coil (CC) region [3]. While almost all TRIM proteins have these
domains, ATDC contains the B1-B2-CC domains but lacks the RING
domain. Several TRIM family members are involved in various cellular
processes such as transcriptional regulation, cell growth, apoptosis,development and oncogenesis [4]. So far, it has been reported that
TRIM proteins including TRIM19/promyelocytic leukemia protein
(PML), TRIM24/transcriptional intermediary factor 1α (TIF1α) and
TRIM27/RET ﬁnger protein (RFP) have oncogenic activities as a result
of chromosomal translocations [5–7].
Though it has been reported that TRIM29 appears to be localized
primarily to the cytoplasm, the function of TRIM29 in physiologic or
pathologic processes has not been fully elucidated. TRIM29 has been
reported to be overexpressed in lung, bladder, colorectal, ovarian and
endometrial cancers and in multiple myeloma. Furthermore, a recent
study has shown correlations of ATDC expression in gastric cancer
with poor histological grade, large tumor size, great extent of tumor
invasion and lymph node metastasis.
Tat-interactive protein 60 (Tip60) was originally identiﬁed as a
cellular acetyltransferase protein that interacts with Tat derived from
human immunodeﬁciency virus-1 (HIV-1) [8]. Tip60 has divergent
functions for many processes such as cellular signaling, DNA damage
repair, cell cycle, checkpoint control and apoptosis [9]. Tip60 is a tightly
regulated transcriptional coregulator [10,11], acting in a large multi-
protein complex for a range of transcription factors including androgen
receptor,Myc, STAT3,NF-κB, E2F1 andp53 [12–17]. Tip60 likely plays an
important role in the p53 pathway [18], but the mechanism by which
Tip60 acts on p53 has not been elucidated. Tip60 can acetylate p53 on
lysine 120 (K120),which is localizedwithin theDNA-binding domain of
p53. This domain, in whichmutations are often found in human cancer,
is an important region for posttranslational modiﬁcation of p53,
followed by the regulation for transcription or apoptosis. A conservative
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activation of p53 proapoptotic target genes (Bax and Puma). However,
acetylation of K120 in p53 affects proapoptotic promoters but does not
regulate the promoter of p21 [19,20].
In this study, with the aim of elucidating the molecular function of
TRIM29 in carcinogenesis, we identiﬁed Tip60 as a novel TRIM29-
binding protein by using yeast two-hybrid screening. TRIM29 reduced
the acetylation of p53-K120 via change in the localization and/or
degradation of Tip60. We also found that overexpression of TRIM29
promoted cell growth and transforming activity. Moreover, we found
that TRIM29 suppressed apoptosis induced byUV irradiation in HCT116
cell lines. These ﬁndings may provide evidence for the importance of
TRIM29 in carcinogenesis.
2. Materials and methods
2.1. Cell culture
HEK293T and HCT116 cell lines were cultured under an atmosphere
of 5% CO2 at 37 °C in DMEM (Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum (Invitrogen, Carlsbad, CA). NIH 3T3 cells lines
were cultured under the same conditions in DMEM supplementedwith
10% calf serum (CS, Camblex, Walkersville, MD). ACC3 cells were
cultured under the same conditions in RPMI1640 supplemented with
10% FBS. The proteasome inhibitor LLnN was purchased from Roche
(Branchburg, NJ).
2.2. Cloning of cDNAs and plasmid construction
Human TRIM29 cDNAs were ampliﬁed from HeLa cDNA by PCR
with BlendTaq (Takara, Tokyo, Japan) using the following primers: 5′-
GCGATGGAAGCTGCAGATGCCTCC-3′ (TRIM29-sense) and 5′-AGCT
CATGGGGCTTCGTTGGACCC-3′ (TRIM29-antisense). The ampliﬁed
fragments were subcloned into pBluescript II SK+ (Stratagene, La
Jolla, CA). FLAG-tagged TRIM29 cDNA was then subcloned into pCR
(Invitrogen) for expression in eukaryotic cells. pBTM116 and pACT2
(Clontech Laboratories, Inc. Mountain View, CA) were used for a yeast
two-hybrid system. Human Tip60 cDNA was kindly provided by
Dr. Ikura (Tohoku University).
2.3. Yeast two-hybrid screening
Complementary DNA encoding the full-length of human TRIM29
was fused in-frame to the nucleotide sequence for the LexA domain
(BD) in the yeast two-hybrid vector pBTM116. To screen proteins that
interact with TRIM29, we transformed yeast strain L40 (Invitrogen)
stably expressing the corresponding pBTM116 vector with a human
HeLa cDNA library (Clontech).
2.4. Transfection, immunoprecipitation, and immunoblot analysis
HEK293T cells were transfected by the calcium phosphate method
and lysed in a solution containing 50 mmol/L Tris–HCl (pH 7.4),
150 mmol/L NaCl, 1% Nonidet P-40, leupeptin (10 μg/mL), 1 mmol/L
phenylmethylsulfonyl ﬂuoride, 400 μmol/L Na3VO4, 400 μmol/L EDTA,
10 mmol/L NaF, and 10 mmol/L sodium pyrophosphate. The cell
lysates were centrifuged at 16,000g for 10 min at 4 °C, and the
resulting supernatant was incubated with antibodies for 2 h at 4 °C.
Protein A-sepharose (Amersham Pharmacia Biotech Inc, Piscataway,
NJ) that had been equilibrated with the same solution was added to
the mixture, which was then rotated for 1 h at 4 °C. The resin was
separated by centrifugation, washed ﬁve times with ice-cold lysis
buffer, and then boiled in SDS sample buffer. Immunoblot analysis
was performed with the following primary antibodies: anti-FLAG
(1 μg/mL; M2 or M5, Sigma), anti-HA (1 μg/mL; HA.11/16B12,
Covance, Berkeley, CA), anti-HA (1 μg/mL; Y11, Santa Cruz Biotech-nology, Santa Cruz, CA), anti-TRIM29 (1:1,000 dilution, IMGENEX, San
Diego, USA), anti-β-actin (1 μg/mL; AC15, Sigma), anti-GAPDH (1 μg/
mL; 6 C5, Applied Biosystems, Foster City, CA), anti-Tip60 (1:1,000
dilution, AmProx, Carlsbad, CA) and anti-Tip60 (1:1,000, Calbiochem,
San Diego, CA). Immune complexes were detected with horseradish
peroxidase-conjugated antibodies to mouse or rabbit IgG (1:10,000
dilution, Promega, Madison, WI) and an enhanced chemilumines-
cence system (Amersham).
2.5. Immunoﬂuorescent staining
HeLa cells expressing FLAG–TRIM29 or HA-Tip60 grown on a glass
cover were ﬁxed for 20 min at room temperature with 4% formalde-
hyde in PBS and then incubated for 1 h at room temperature with
primary antibodies to FLAG or HA in PBS containing 0.1% bovine
serum albumin and 0.1% saponin. They were then incubated with
Alexa546-labeled goat polyclonal antibodies to mouse immunoglob-
ulin or Alexa488-labeled goat polyclonal antibodies to rabbit
immunoglobulin (Invitrogen) at a dilution of 1:2,000. The cells were
covered with a drop of GEL/MOUNT (Biomeda, Foster City, CA) and
then photographedwith a CCD camera (DP71, Olympus, Tokyo, Japan)
attached to an Olympus BX51 microscope.
2.6. Retroviral infection
Retroviral expression vectors for TRIM29 and c-Src(Y527F) were
constructed with pMX-puro and pMX-hyg, respectively. Retroviral
expression vectors were kindly provided by Dr. Kitamura (University
of Tokyo) [21]. For retrovirus-mediated gene expression, NIH 3T3 cells
were infected with retroviruses produced by Plat-E packaging cells
and then cultured in the presence of puromycin (2 μg/mL, Sigma) or
hygromycin B (0.2 mg/mL, Sigma). HCT116 cells were infected with
retroviruses produced by Plat-A packaging cells and then cultured in
the presence of puromycin (0.5 μg/mL).
2.7. Exposure to UVC
For single exposure of HCT116 cells in a monolayer to UVC, 2×105
cells were seeded in a 6-cm dish two days before exposure. The cells
werewashedwithphosphate-buffered saline (PBS) and exposed toUVC
(λ=254 nm) at different doses from 10 to 80 J/cm2 (UV crosslinker,
Funakoshi, Japan).
2.8. In vivo p53 acetylation assay
The human colon cancer cell line HCT116 was treated with UV as
DNA damage. The cells were then incubated for 12 h to induce
acetylation of p53 in the presence of an inhibitor of deacetylase,
trichostatin (0.5 μM). Cell lysateswere immunoprecipitatedwith anti-
p53 antibody (Clone DO-1, sc-126, Santa Cruz) and then immunoblot
analysis was performedwith anti-K120-acetylated p53 (AcK120-p53)
(10E5, Abnova, Taipei City, Taiwan).
2.9. RNA interference
Small interferingRNA (siRNA)oligonucleotide sequences speciﬁc for
human TRIM29 and p53 mRNAwere designed by Silencer Predesigned
siRNA (Ambion, Foster City, CA). pSUPER.retro.puro. vectors (OligoEn-
gine, Seattle, WA) containing shRNAswere used for infection into ACC3
or HCT116 cells. After 24 h, the resulting cell lines were used for
immunoblot analysis to detect the expression level of TRIM29.
2.10. Cell proliferation assay
HCT116 cells in which TRIM29 or an empty vector (Mock) was
stably expressed by using a retroviral expression system were seeded
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number at indicated times.2.11. Focus formation assay
NIH 3T3 cell lines stably expressing FLAG–TRIM29 and/or c-Src
(Y527F) were plated at a density of 1×104 cells in 60-mm dishes with
drug selection. After 2 weeks, conﬂuent cells on disheswere stained by
crystal violet and focus formation was observed under a microscope.2.12. Colony formation assay
For the colony formation assay, 1×105 cells were plated in 60-mm
dishes containing 0.4% soft agar and cultured for 2 weeks. Thenumbers
of colonieswith a diameter of N0.125 mmin randomized areas (1 cm2)
were counted.2.13. Apoptosis assay
Assessment of apoptosis was performed by measurement of the
intensity of the sub-G1 peak. For the sub-G1 peak, HCT116 cells were
incubatedwith orwithoutUV irradiation (10–80 J/m2) for 18 and 24 h.
The cellswere treatedwith propidium iodide and then the sub-G1 peak
was analyzed with a FACSCalibur ﬂow cytometer (Becton Dickinson,
San Jose, CA).2.14. Statistical analysis
The unpaired Student's t test was used to determine the statistical
signiﬁcance of experimental data.Fig. 1. TRIM29 interacts with Tip60. (A) Tip60 was isolated by yeast two-hybrid screening u
assay. (B) In vivo binding assay between FLAG–TRIM29 and HA-Tip60. FLAG–TRIM29 and HA
immunoprecipitated with anti-HA antibody and immunoblotted with anti-FLAG and an
immunoprecipitation (IP) was also subjected to immunoblot analysis (IB). (C) In vivo bind
transfected into HEK293T cells. Cell lysates (WCL) were immunoprecipitated with anti-Tip
portion of the cell lysate corresponding to 3% of the input for immunoprecipitation (IP) was a
exogenous TRIM29. HCT116 cells were transfected with different amounts of FLAG–TRIM29.
anti-β-actin antibodies. (E) Proteasome-dependent degradation of Tip60 by TRIM29. HCT116
LLnL (10 μM) for indicated times. Cell lysates were then subjected to immunoblot analysis3. Results
3.1. TRIM29 interacts with and mediates degradation of Tip60
To identify proteins that interact with TRIM29, we screened a
pACT2HeLa cDNA librarywith pBTM116-hTRIM29plasmid as a bait by
using a yeast two-hybrid system. We obtained 60 grown clones from
1.25×106 transformants in selection medium. Finally, we obtained
two positive clones that may interact with TRIM29 in this screening:
Tip60 and Xab2. Interaction between TRIM29 and Tip60 was again
conﬁrmed by a β-galactosidase assay (Fig. 1A). To examine whether
TRIM29 physically interacts with Tip60 in mammalian cells, we
performed an in vivo binding assay using cells transfected with
expression vectors. We expressed FLAG–TRIM29 together with HA-
Tip60 in HEK293T cells. Cell lysates were subjected to immunopre-
cipitation with an antibody to HA, and the resulting precipitates were
subjected to immunoblot analysis with an antibody to FLAG. FLAG–
TRIM29 was co-precipitated by the antibody to HA, indicating that
TRIM29 speciﬁcally interacts with Tip60 (Fig. 1B). To further conﬁrm
the interaction between endogenous Tip60 and FLAG–TRIM29, we
performed an in vivo binding assay using cells transfected with an
expression vector encoding FLAG–TRIM29. Immunoblot analysis
showed that FLAG–TRIM29 was co-precipitated by the antibody to
Tip60, indicating that TRIM29 speciﬁcally interacts with Tip60
(Fig. 1C).
It has been reported that some TRIM family proteins form
homodimers or heterodimers. There is a possibility that even though
TRIM29 has no RING-ﬁnger domain, TRIM29 interactswith other TRIM
family proteins with a RING-ﬁnger domain and affects the stability of
Tip60. To examine whether TRIM29 ubiquitinates Tip60, we per-
formed an in vivo ubiquitination assay. However, overexpression of
TRIM29 did not enhance polyubiquitination of HA-Tip60 (data not
shown).We further examined the effect of TRIM29 on the degradationsing TRIM29 as bait. Interaction of TRIM29 and Tip60 was conﬁrmed by β-galactosidase
-Tip60 expression vectors were transfected into HEK293T cells. Cell lysates (WCL) were
ti-HA antibodies. A portion of the cell lysate corresponding to 3% of the input for
ing assay between FLAG–TRIM29 and endogenous Tip60. FLAG–TRIM29 vectors were
60, anti-FLAG or control antibody and immunoblotted with anti-TRIM29 antibodies. A
lso subjected to immunoblot analysis (IB). (D) Down-regulation of endogenous Tip60 by
Cell lysates were then subjected to immunoblot analysis with anti-Tip60, anti-FLAG and
cells transfected with an expression vector encoding FLAG–TRIM29 were cultured with
with anti-Tip60, anti-FLAG and anti-β-actin antibodies.
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overexpression of TRIM29 attenuated the expression of endogenous
Tip60 in a TRIM29 dose-dependent manner (Fig. 1D). To determine
whether the decrease in expression level of Tip60 is enhanced by
proteasome-dependent degradation, we performed immunobolot
analysis with anti-Tip60 antibody using cell lysates incubated with
the proteasome inhibitor LLnL. Immunoblot analysis showed that the
proteasome inhibitor LLnL inhibited the degradation of Tip60,
suggesting that degradation of Tip60 by TRIM29 is dependent on
proteasome activity (Fig. 1E).
3.2. TRIM29 colocalizes with Tip60
We investigated the effect of TRIM29 on subcellular localization of
Tip60. To test each localization, we performed immunoﬂuorescent
staining of TRIM29 and Tip60. We transiently transfected FLAG–
TRIM29 and HA-Tip60 expression vectors into HeLa cells and stained
the cells by using anti-FLAG and anti-HA antibodies. Tip60was usually
expressed in the nucleus, whereas TRIM29 was expressed in the
cytosol. Overexpression of TRIM29 caused a decrease in nuclear
staining of Tip60 and an increase in localization of Tip60 in the cytosol
(Fig. 2). Similar results were obtained by using COS7 cells (data not
shown). These ﬁndings suggest that TRIM29 regulates Tip60 localiza-
tion and then TRIM29 affects the physiological function of Tip60.
3.3. TRIM29 reduces acetylation of p53 at K120 by Tip60
Lysine (K) 120 is located in the L1 loop of the DNA-binding core
domain of p53 and is conserved in all known specieswhich encodep53
including humans, mice, Drosophila melanogaster and Caenorhabditis
elegans, suggesting a critical role for this residue in p53 function [20].
Tumor-associated genemutations of K120have often beenobserved in
several different types of human cancer [19,22]. Furthermore, it has
been reported that Tip60 induces its acetylation speciﬁcally at K120 in
the DNA-binding domain and is required for both cell growth arrest
and apoptosis mediated by p53 [20]. Taken together, K120 acetylation
by Tip60 is crucial for p53-dependent apoptosis. To determine theFig. 2. TRIM29 affects subcellular localization of Tip60. HeLa cells were transiently transfect
tagged TRIM29. Cells were ﬁxed and stained with anti-FLAG and anti-HA antibodies. Scalecondition of DNA damage response to induce Tip60-mediated p53
acetylation, we performed immunoblot analysis using an antibody
speciﬁc to K120-acetylated p53 (AcK120-p53) with the human
colorectal carcinoma cell line HCT116 damaged by UV irradiation.
Twenty hours after exposure to UV light (20–80 J/m2), whole-cell
extracts at each UV dose were immunoprecipitated with anti-p53
antibody and then immunoblotted with antibodies speciﬁc for
AcK120-p53. Immunoblot analysis showed that UV-mediated DNA
damage induces acetylation of p53 at K120 (Fig. 3A).
Next, to elucidate the role of TRIM29 in DNA damage-induced p53
activation by Tip60, we testedwhether TRIM29 affects K120 acetylation
of endogenous p53. Twenty hours after exposure to UV light (80 J/m2),
HCT116 cells stably expressing TRIM29or anempty vector (Mock)were
harvested and the acetylation of p53 was analyzed. Immunoblot
analysis showed that HCT116 cells stably expressing TRIM29 had no
obvious difference in p53 accumulation uponDNAdamage compared to
Mock cells but had signiﬁcantly reduced levels of acetylated p53 atK120
(Fig. 3B). These results suggest that TRIM29 reduces acetylation of p53
at K120 by Tip60.3.4. TRIM29 suppresses apoptosis induced by UV
Given that TRIM29 causes a decrease in Tip60-mediated acetyla-
tion of p53 at K120, overexpression of TRIM29 may inhibit p53-
dependent apoptosis by UV treatment. We analyzed the susceptibility
to UV-mediated DNA damage using the HCT116 cell line infected with
a retrovirus encoding FLAG–TRIM29 or the corresponding empty
vector (Mock). The resulting cell lineswere treatedwithUV, incubated
for 24 h, and stained with propidium iodide (PI), and the sub-G1 peak
was measured by a ﬂowcytomer to detect apoptotic cells according to
DNA content. Flowcytometric analysis showed that approximately
38.6% ofMock cellswere apoptotic cells, whereas only 8.3% of TRIM29-
expressing cells were counted as apoptotic cells after 24-h UV
treatment by ﬂowcytometric analysis (Fig. 4A and B). Next, we
performed an apoptosis assay using low doses of UV (10 and 20 J/m2).
The apoptosis assay showed that overexpression of TRIM29 also
suppressed apoptosis induced by low doses of UV (10 and 20 J/m2),ed with expression vectors encoding HA-tagged Tip60 and different amounts of FLAG-
bar, 10 µm.The green and red colors represent TRIM29 and Tip60, respectively.
Fig. 3. TRIM29 reduces acetylation of p53 at K120 by Tip60. (A) HCT116 cells were
treated with UV (20, 40 or 80 J/m2) and cultured for 12 h. Cell lysates (WCL) were
immunoprecipitated with anti-p53 antibody (DO-1) and immunoblotted with anti-
K120-acetylated (AcK120)-p53 antibody. (B) In vivo acetylation of p53 at K120 by
Tip60. HCT116 cell lines stably expressing TRIM29 or an empty vector (Mock) were
treated with or without UV (80 J/m2) and then cultured for 4 or 8 h. Total cell extracts
were immunoprecipitated with anti-p53 antibody (DO-1) and then immunoblotted
using anti-FLAG, anti-Tip60, anti-AcK120-p53 and anti-p53 (DO-1) antibodies.
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UV irradiation (Fig. 4C). To clarify the relationship between TRIM29
and p53 in UV-induced apoptosis, p53-knockdown cells (HCT116.
p53kd)were used for a UV-mediated apoptosis assay. The HCT116 cell
line in which p53 was knocked down was further transfected with an
expression vector encoding TRIM29 (HCT116.p53kd.TRIM29)
(Fig. 4D). We performed an apoptosis assay using these cell lines.
UV-induced apoptosis was inhibited in HCT116.p53kd cells compared
with mock. UV-induced apoptosis in HCT116.p53kd.TRIM29 was
almost the same as apoptosis in HCT116.p53kd cells and apoptosis in
HCT116.TRIM29, indicating that UV-induced apoptosis in HCT116.
p53kd is not affected by overexpression of TRIM29 (Fig. 4E). These
ﬁndings suggest that TRIM29 does not function as a regulator of an
apoptotic pathway other than the p53-mediated apoptotic pathway.3.5. TRIM29 affects cell growth and anchorage-independent growth
It has been reported that overexpression of TRIM29 promotes cell
growth of the osteosarcoma cell line Saos-2 and the breast cancer cell
line BT-549 [23]. We further conﬁrmed the effect of TRIM29 on cell
growth using HCT116 cells. HCT116 cells overexpressing FLAG–
TRIM29 or an empty vector (Mock) were seeded and cell numbers
were counted at indicated times. Overexpression of TRIM29 signiﬁ-
cantly increased the growth rate compared with that of Mock
(Fig. 5A). Next, to determine whether TRIM29 affects cell transfor-
mation by the active form of c-Src (c-Src(Y527F)), we established an
NIH 3T3 cell line stably expressing the active form of c-Src(Y527F) by
retroviral infection. The resulting cell line was further infected with
recombinant retroviruses encoding FLAG–TRIM29 (Fig. 5B). The effect
of TRIM29 on cell proliferation was conﬁrmed by focus formation
assays using these cell lines. Many foci were formed by the NIH 3T3
cell line expressing c-Src(Y527F), and the NIH 3T3 cell line expressing
both c-Src(Y527F) and TRIM29 formed more foci, suggesting that
TRIM29 enhances the transformation by oncogenic activity of c-Src
(Y527F) (Fig. 5C). The ability of these NIH 3T3 cell lines to form
colonies in soft agar was also analyzed to evaluate their ability to
undergo anchorage-independent growth. Cells that had not been
infected c-Src(Y527F) formed few colonies, whereas cells expressing
c-Src(Y527F) formedmany colonies. The combination of c-Src(Y527F)
and TRIM29 increased the ability for anchorage-independent growth
(Fig. 5D and E). These ﬁndings suggest that TRIM29 functions as a
positive regulator for anchorage-independent growth.3.6. Knockdown of TRIM29 expression causes cell morphological changes
followed by apoptosis
To knockdown endogenous TRIM29, we introduced shRNA speciﬁc
for human TRIM29 (sh-1, sh-2, sh-3) or non-targeting shRNA as a
control (sh-control) into the ACC3 cell line in which TRIM29 is highly
expressed. TheHCT116 cell linewas used as a negative control because
we conﬁrmed that TRIM29 is not expressed in HCT116 cells (Fig. 6A).
Immunoblot analysis showed that the expression level of TRIM29was
reduced by shRNA for TRIM29 (sh-2 and sh-3). In contrast, TRIM29
protein levels were not signiﬁcantly decreased in cells infected with
sh-1 (Fig. 6B). The shRNA for TRIM29 (sh-2 and sh-3) caused
morphological changes, including rounding of cell shapes and
decrease in size, and detachment from the dish, consistent with
phenomena often observed in apoptosis (Fig. 6C). The HCT116 cell line
was used as a negative control becausewehave already conﬁrmed that
TRIM29 is not expressed in HCT116 cells. Similar effects were not
observed using HCT116 cells. These ﬁndings suggest that TRIM29 is
required for cell viability for TRIM29-expressing cells and that TRIM29
functions as a positive regulator for cell growth.4. Discussion
Our studies demonstrate a functional role of TRIM29 in human
tumorigenesis. TRIM29 has been reported to be overexpressed in
lung, bladder, colorectal, ovarian, gastric, pancreatic and endometrial
cancers and in multiple myeloma [24–32]. Interestingly, opposite
results were obtained in melanoma and in breast, head and neck, and
prostate cancers [33–38]. The signiﬁcance of such a paradoxical
pattern of TRIM29 expression in cancer may suggest that the function
of TRIM29 is dependent on cellular or tissue context. Recently, it has
been reported that TRIM29 is highly expressed in gastric cancer with
poor histological grade, larger tumor size, greater extent of tumor
invasion and lymph node metastasis [29]. TRIM29 may thus play a
pivotal role in differentiation, proliferation, and progression of gastric
cancer cells. Taken together, it is important to unveil the molecular
mechanism for regulation of the expression level of TRIM29 and
furthermore to analyze gene mutation or single nucleotide poly-
morphisms of the TRIM29 gene using several cancer tissues or cancer
cell lines in the future.
Several recent reports have shown the role of TRIM29 in tumori-
genesis examinedon the basis of functional studies. A recent report has
shown that TRIM29 is an important positive regulator of β-catenin-
dependent signaling in pancreatic cancer [30]. In normal pancreatic
cells lacking TRIM29, Disheveled-2 (Dvl-2) is localized in the
cytoplasm and is not bound to the axin/glycogen synthase kinase 3β
(GSK-3β)/APC complex, which degrades and ubiquitinates phosphor-
ylated β-catenin and targets it for ubiquitin-mediated degradation. In
pancreatic cancer cells expressing high levels of TRIM29, TRIM29binds
to and stabilizes Dvl-2, resulting in the release of β-catenin from the
destruction complex, increased β-catenin levels, and subsequent
activation of downstream β-catenin/TCF-regulated target genes.
Thus, TRIM29 likely stabilizes β-catenin via inhibition of Dvl-2, a
negative regulator of GSK-3β in Wnt/β-catenin signaling. This report
showed one of the functional roles of TRIM29 in human tumorigenesis
and indicated the possibility of TRIM29 being a potential therapeutic
target in pancreatic cancer.
Ionizing irradiation induced apoptosis to a greater extent in
AT5BIVA cells and ATDC partially suppressed this irradiation-induced
apoptosis. It has been reported that ATDC increases cell proliferation
via inhibition of p53 nuclear activities [40]. The association of p53 and
ATDC results in p53 sequestration outside the nucleus. These results
provide novel mechanistic insights into the function of ATDC and offer
an explanation for how ATDC promotes cancer cell proliferation. We
also demonstrated that TRIM29 functions as an oncogene as revealed
Fig. 4. TRIM29 suppresses apoptosis induced by UV treatment. (A)Measurement of sub-G1 peak. HCT116 cell lines were incubated for 0, 12, 18 and 24 h after UV treatment (20 J/m2).
The cells were treated with propidium iodide and then sub-G1 peaks were analyzed with a FACSCalibur ﬂow cytometer. (B) Quantiﬁcation of apoptotic cell fraction. Percentages of
apoptotic cells at each time in (A) are shown. (C) Inhibition of UV-mediated apoptosis by TRIM29 at a low dose of UV irradiation. HCT116 cell lines were incubated for 18 h after UV
treatment (0, 10 or 20 J/m2). The cells were treated with propidium iodide, and then sub-G1 peaks were analyzedwith a FACSCalibur ﬂow cytometer. Percentages of apoptotic cells at
the indicated times are shown. (D) Establishment of cell lines in which FLAG–TRIM29 is overexpressed and p53 is knocked down. HCT116 cells were infected with a retrovirus
containing a human p53 short hairpin RNA (shRNA) or mock sequence and then transfected with an expression vector encoding FLAG-tagged TRIM29. Each expression was checked
by immunoblot analysis using anti-53, anti-FLAG and anti-GAPDH antibodies. (E) Effect of UV-mediated apoptosis by TRIM29 and p53. HCT116 cell lines in which p53 is knocked
down and/or TRIM29 is overexpressed were incubated for 18 h after UV treatment (20 J/m2). The cells were treated with propidium iodide, and then sub-G1 peaks were analyzed
with a FACSCalibur ﬂow cytometer.
1250 T. Sho et al. / Biochimica et Biophysica Acta 1813 (2011) 1245–1253by results of a cell proliferation assay, focus formation assay and
colony formation assay in our study.
Others have reported that the amount of TRIM29 increased in
keratinocytes after exposure to UVB and that knockdown of TRIM29by short-hairpin RNA interference decreases the viability of kerati-
nocytes after UVB exposure, suggesting that TRIM29 participates in
the survival of differentiating keratinocytes that are exposed to UVB
and pro-death stimuli [41]. We also showed that knockdown of
Fig. 5. TRIM29 affects cell growth and colony formation activity. (A) Acceleration of cell proliferation by TRIM29. HCT116 cells infected with a retrovirus encoding FLAG–TRIM29 or
the corresponding empty vector (Mock) were seeded at 3×104 cells in six-well plates and harvested for determination of cell number at indicated times. Data are means±SD of
values from three independent experiments. (B) Establishment of cell lines expressing FLAG–TRIM29 and/or c-Src(Y527F). NIH 3T3 cells infected with a retrovirus encoding FLAG–
TRIM29 or the corresponding empty vector (Mock). NIH 3T3 cell lines were further infected with a retrovirus for c-Src(Y527F). Each expression was checked by immunoblot analysis
using anti-FLAG, anti-Src and anti-β-actin antibodies. (C) Focus formation assay of NIH 3T3 cells infected with retrovirus vectors encoding FLAG–TRIM29 and/or c-Src(Y527F). Cell
lines were plated at a density of 1×104 cells in 60-mm dishes with drug selection. After 2 weeks, conﬂuent cells on dishes were stained by crystal violet and focus formation was
observed under a microscope. Scale bar, 0.1 mm. (D) Colony formation assay of NIH 3T3 cells infected with retrovirus vectors encoding FLAG–TRIM29 and/or c-Src(Y527F). NIH 3T3
cell lines were seeded at 1×105 cells in 60-mm dishes containing 0.4% soft agar and cultured for 2 weeks. Scale bar, 0.1 mm. (E) Quantiﬁcation of colony numbers on soft agar. The
numbers of colonies with a diameter of more than 0.125 mm in randomized areas (per 1 cm2) were counted. Data are means±SD of values from three independent experiments.
P values for the indicated comparisons were determined by Student's t-test.
1251T. Sho et al. / Biochimica et Biophysica Acta 1813 (2011) 1245–1253TRIM29 with shRNA causes morphological changes of ACC3 cells in
which apoptosis is likely to be induced.
We found that TRIM29 interacts with one of the MYST family
acetyltransferases, Tip60, and that overexpression of TRIM29 atten-
uated expression of endogenous Tip60 in a TRIM29 dose-dependent
manner. We could not ﬁnd that overexpression of TRIM29 enhances
polyubiquitination of Tip60. However, overexpression of TRIM29
caused a decrease in nuclear staining of Tip60. These ﬁndings suggest
that TRIM29 affects the stability of Tip60 via subcellular translocation
from the nucleus to the cytosol.
Many recent studies have shown the role for Tip60 in tumorigen-
esis. Tip60 causes UV-induced transcription of several p53 targets.Post-translational modiﬁcation of the DNA-binding domain of p53
including acetylation of K120 occurs rapidly after DNA damage and its
acetylation is catalyzed by Tip60. Tip60 is required for both cell
growth arrest and apoptosis mediated by p53 [39]. Interestingly, this
modiﬁcation is crucial for p53-dependent apoptosis but is dispensable
for its mediated growth arrest. Mutation of lysine 120 to arginine,
which occurs in human cancer, and the corresponding acetylation-
defective tumor mutant (K120R) abrogates p53-mediated apoptosis
but not growth arrest. K120R mutation selectively blocks transcrip-
tion of pro-apoptotic target genes such as Bax and Puma, while the
non-apoptotic targets p21 and MDM2 remain unaffected. Consistent
with this, depletion of Tip60 inhibits the ability of p53 to activate Bax
Fig. 6. Effect of TRIM29 RNAi on cell morphology. (A) Expression of TRIM29 in HCT116 and ACC3 cells. Cell lysates from HCT116 and ACC3 cells were subjected to immunoblot
analysis with anti-TRIM29 or anti-β-actin antibody (B) ACC3 cells were infected with virus containing a human TRIM29 short hairpin RNA (shRNA) sequence (sh-1, sh-2 and sh-3) or
control shRNA (Mock). At 24 h after infection, whole cell lysates were analyzed by immunoblotting using anti-TRIM29 and anti-β-actin antibodies. (C) Microscopic analysis of
TRIM29 shRNA-infected ACC3 cells. HCT116 cells in which TRIM29 is not expressed were used as negative controls. Seventy-two h after infection with sh-1, sh-2 or sh-3, cells were
observed by microscopy. Scale bar, 25 µm.
1252 T. Sho et al. / Biochimica et Biophysica Acta 1813 (2011) 1245–1253and Puma transcription [19,20]. Actually, in this study, we demon-
strated that overexpression of TRIM29 reduces acetylation of p53 at
K120 by Tip60 and suppresses apoptosis induced by UV irradiation,
suggesting that TRIM29 functions as a negative regulator of p53 via
inhibition of Tip60-mediated acetylation.
In conclusion, our observations indicate that TRIM29 is a positive
mediator affecting tumor growth, apoptosis, and resistance to UV
irradiation, and results of further studies on TRIM29may be useful for
establishing new therapies for cancers, immunological deﬁciencies,
and neurological degeneration accompanying AT. Moreover, analysis
by a genetic approach using transgenic or knock-outmice is needed to
clarify physiological functions of TRIM29.
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